D-0263-2021 Class II Terminated

Recalled by Ascend Laboratories LLC — Parsippany, NJ

FDA drug recall D-0263-2021 was initiated by Ascend Laboratories LLC on Jan 22, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit. The recall status is terminated (terminated Dec 2, 2022). Affected quantity: 14,205 100 mL bottles.

Recall details

Product Type
Drugs
Report Date
Feb 24, 2021
Initiation Date
Jan 22, 2021
Termination Date
Dec 2, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14,205 100 mL bottles

Product description

Cephalexin for Oral Suspension, USP 250 mg per 5 mL, 100 ml (when mixed) Rx Only, Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-88

Reason for recall

CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.

Distribution pattern

Nationwide in the USA

Code information

Lot # 19144841, Exp 9/2021; 20141673 Exp 4/2022.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0263-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0263-2021. Report a data issue: hello@regdatalab.com.